May 25, 2023 10:24 AM EDT

Boehringer Ingelheim extends 2020 collab with Oxford BioTherapeutics; European biotechs claim positive PhI I/O data

Paul Schloesser

Associate Editor

Kyle LaHucik

Senior Reporter

Oxford BioTherapeutics said Thursday that it has extended its second collaboration with Boehringer Ingelheim for another two years. The biotech said …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Boehringer Ingelheim extends 2020 collab with Oxford BioTherapeutics; European biotechs claim positive PhI I/O data

Paul Schloesser

Associate Editor

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

New fund will pressure flailing biotechs, as investor frustration boils over

FDA chief Makary talks expediting drug approvals, RIFs and the abortion pill

Akeso shares new data suggesting it can beat Keytruda on survival, wins China approval

AbbVie commits $10B to expand US footprint with the threat of tariffs ahead

J&J reports durability data for bladder cancer 'pretzel' drug after FDA filing

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Boehringer In­gel­heim ex­tends 2020 col­lab with Ox­ford Bio­Ther­a­peu­tics; Eu­ro­pean biotechs claim pos­i­tive PhI I/O da­ta

Associate Editor

Senior Reporter

Sign up to read this article for free.

Gondolabio

Palo Alto, CA, USA

Boehringer Ingelheim extends 2020 collab with Oxford BioTherapeutics; European biotechs claim positive PhI I/O data